Literature DB >> 8883617

Antigenic determinants on HIV-1 envelope glycoproteins: a dickens of a time with oligomer twist.

K A Kent1, J Robinson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883617

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 2.  A vaccine for HIV type 1: the antibody perspective.

Authors:  D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains.

Authors:  Jonathan D Steckbeck; Irina Orlov; Andrew Chow; Heather Grieser; Kenneth Miller; JoAnne Bruno; James E Robinson; Ronald C Montelaro; Kelly Stefano Cole
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

Authors:  R I Connor; B T Korber; B S Graham; B H Hahn; D D Ho; B D Walker; A U Neumann; S H Vermund; J Mestecky; S Jackson; E Fenamore; Y Cao; F Gao; S Kalams; K J Kunstman; D McDonald; N McWilliams; A Trkola; J P Moore; S M Wolinsky
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.